<DOC>
	<DOCNO>NCT00330174</DOCNO>
	<brief_summary>STUDY OBJECTIVES : The primary objective study compare safety efficacy acamprosate versus placebo treatment alcohol dependence adult co-occurring mood anxiety disorder ( specifically , depression ( MDE ) , generalize anxiety disorder ( GAD ) social anxiety disorder ) . Secondary objective evaluate effect acamprosate treatment mood anxiety disorder . STUDY DESIGN : This randomize , double-blind , placebo-controlled trial evaluate acamprosate treatment alcohol dependence adult outpatient concurrent mood and/or anxiety disorder . The active study phase 12 week duration . There two-week screening period , follow 12 week study medication follow-up assessment 14 week randomization . STUDY POPULATION : A total 90 ( 30 per site ) men woman age 18-60 year current diagnosis alcohol dependence well current DSM-IV diagnosis either MDE , GAD and/or social anxiety recruit participate study . Only individual whose psychiatric disorder stable randomized acamprosate placebo . Three site participate trial . TREATMENTS : Eligible participant randomly assign receive either acamprosate matching placebo 12 week . EFFICACY ASSESSEMENTS : The primary efficacy outcome measure cumulative day abstinent measure self-report .</brief_summary>
	<brief_title>Acamprosate Alcoholics With Comorbid Anxiety Depression</brief_title>
	<detailed_description>Participants meet inclusion criterion none exclusion criterion randomize receive either acamprosate placebo 1:1 ratio . Participants instructed take ( 2 ) 333 mg tablet three time day . Participants see weekly 12 week 14 week randomization . At weekly visit , participant ask substance use possible adverse event . They also vital sign weight measure visit . Psychiatric assessment , include MADRS , HAM-A , Liebowitz Social Anxiety Scale , Hospital Anxiety Depression Scale perform week 2 , 4 , 8 , 12 . Alcohol crave assess use Obsessive Compulsive Drinking Scale baseline monthly . A urine drug screen also perform monthly . A clinical global impression scale complete psychiatric alcohol abuse symptom every visit . A breath alcohol test perform every visit , urine drug screen perform baseline monthly trial .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Phobic Disorders</mesh_term>
	<mesh_term>Acamprosate</mesh_term>
	<criteria>1 . Adults age 1860 2 . Meet DSMIV criterion current ( past 90 day ) alcohol dependence 3 . Must identify alcohol primary substance abuse 4 . Meet DSMIV criterion current major depressive episode , GAD and/or social anxiety disorder 5 . Have stable psychiatric condition , evidence baseline CGI change score 4 time initial screen baseline visit , receive psychotropic medication , must stable dose medication least one month prior baseline . 6 . Must negative urine drug screen baseline visit ; UDS may repeat twice obtain negative UDS 7 . May receive medication treatment anxiety/mood disorder long dosage stable 4 week prior randomization . 8 . May engage psychosocial treatment alcohol dependence mood/anxiety disorder . 9 . Must abstain alcohol least 3 consecutive day 21 day prior medication initiation 10 . Subjects must able adequately provide informed consent function intellectual level sufficient allow accurate completion assessment instrument 11 . Subjects must consent random assignment , willing commit medication treatment followup assessment 12 . CIWAAr scale 8 less baseline visit 1 . Individuals primary psychotic disorder bipolar disorder 2 . Individuals meet DSMIV criterion current ( past 90 day ) dependence substance alcohol , caffeine nicotine 3 . Individuals uncontrolled neurologic condition could confound result study 4 . Individuals uncontrolled medical condition may adversely affect conduct trial jeopardize subject 's safety 5 . Regular use benzodiazepine treatment psychiatric symptom ( define 12 time month prior screen visit ) 6 . Individuals receive pharmacotherapy ( e.g . disulfiram naltrexone ) prevention alcohol relapse 7 . Women childbearing potential lactating refuse use adequate form birth control 8 . Current suicidal homicidal risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Alcoholism</keyword>
	<keyword>Mood</keyword>
	<keyword>Anxiety</keyword>
	<keyword>Acamprosate</keyword>
</DOC>